MDM2 SNP309 contributes to tumor susceptibility: A meta-analysis

Journal of Genetics and Genomics

Volumn 38, Issue 8, 2011, Pages 341-350

  Wo, Xiaoman ^a   Han, Dong ^a   Sun, Haiming ^a   Liu, Yang ^a   Meng, Xiangning ^a   Bai, Jing ^a   Chen, Feng ^a   Yu, Yang ^a   Jin, Yan ^a   Fu, Songbin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer risk; MDM2; Meta analysis; Polymorphism

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; ETHNICITY; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; PROMOTER REGION; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 80051926924     PISSN: 16738527     EISSN: 18735533     Source Type: Journal    
DOI: 10.1016/j.jgg.2011.07.005     Document Type: Article

References (91)

1. Akisik E., Yazici H., Dalay N. ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer. Mol. Biol. Rep. 2010, 1:343-348.
2. Akkiz H., Sumbul A.T., Bayram S., Bekar A., Akgollu E. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Cancer Epidemiol. 2010, 34:448-452.
3. Alazzouzi H., Suriano G., Guerra A., Plaja A., Espin E., Armengol M., Alhopuro P., Velho S., Shinomura Y., Gonzalez-Aguilera J.J., Yamamoto H., Aaltonen L.A., Moreno V., Capella G., Peinado M.A., Seruca R., Arango D., Schwartz S. Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells. J. Med. Genet. 2007, 44:75-80.
4. Alhopuro P., Ylisaukko-Oja S.K., Koskinen W.J., Bono P., Arola J., Jarvinen H.J., Mecklin J.P., Atula T., Kontio R., Makitie A.A., Suominen S., Leivo I., Vahteristo P., Aaltonen L.M., Aaltonen L.A. The MDM2 promoter polymorphism SNP309T G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J. Med. Genet. 2005, 42:694-698.
5. Arva N.C., Gopen T.R., Talbott K.E., Campbell L.E., Chicas A., White D.E., Bond G.L., Levine A.J., Bargonetti J. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J. Biol. Chem. 2005, 280:26776-26787.
6. Ashton K.A., Proietto A., Otton G., Symonds I., McEvoy M., Attia J., Gilbert M., Hamann U., Scott R.J. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol. Oncol. 2009, 113:109-114.
7. Asomaning K., Reid A.E., Zhou W., Heist R.S., Zhai R., Su L., Kwak E.L., Blaszkowsky L., Zhu A.X., Ryan D.P., Christiani D.C., Liu G. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin. Cancer Res. 2008, 14:4010-4015.
8. Boersma B.J., Howe T.M., Goodman J.E., Yfantis H.G., Lee D.H., Chanock S.J., Ambs S. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J. Natl. Cancer Inst. 2006, 98:911-919.
9. Bond G.L., Hu W., Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res. 2005, 65:5481-5484.
10. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., Bargonetti J., Bartel F., Taubert H., Wuerl P., Onel K., Yip L., Hwang S.J., Strong L.C., Lozano G., Levine A.J. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602.
11. Campbell I.G., Eccles D.M., Choong D.Y. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett. 2006, 240:195-197.
12. Capasso M., Ayala F., Avvisati R.A., Russo R., Gambale A., Mozzillo N., Ascierto P.A., Iolascon A. MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness. J. Hum. Genet. 2010, 55:518-524.
13. Chen X., Sturgis E.M., Lei D., Dahlstrom K., Wei Q., Li G. Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. Cancer Res. 2010, 70:7199-7208.
14. Chen Y.L., Chang Y.S., Chang J.G., Wu S.M. Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis. Anal. Bioanal. Chem. 2009, 394:1291-1297.
15. Cho Y.G., Choi B.J., Song J.H., Kim C.J., Cao Z., Nam S.W., Lee J.Y., Park W.S. No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients. Neoplasma 2008, 55:256-260.
16. Chua H.W., Ng D., Choo S., Lum S.S., Li H., Soh L.Y., Sabapathy K., Seow A. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer 2010, 10:88.
17. Cox D.G., Deer D., Guo Q., Tworoger S.S., Hankinson S.E., Hunter D.J., De Vivo I. The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies. Cancer Causes Control 2007, 18:621-625.
18. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
19. Dharel N., Kato N., Muroyama R., Moriyama M., Shao R.X., Kawabe T., Omata M. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin. Cancer Res. 2006, 12:4867-4871.
20. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
21. El Hallani S., Marie Y., Idbaih A., Rodero M., Boisselier B., Laigle-Donadey F., Ducray F., Delattre J.Y., Sanson M. No association of MDM2 SNP309 with risk of glioblastoma and prognosis. J. Neurooncol. 2007, 85:241-244.
22. Ellis N.A., Huo D., Yildiz O., Worrillow L.J., Banerjee M., Le Beau M.M., Larson R.A., Allan J.M., Onel K. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008, 112:741-749.
23. Ezzikouri S., El Feydi A.E., Afifi R., El Kihal L., Benazzouz M., Hassar M., Marchio A., Pineau P., Benjelloun S. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect. Prev. 2009, 32:380-385.
24. Freedman D.A., Wu L., Levine A.J. Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci. 1999, 55:96-107.
25. Gangwar R., Mittal R.D. Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population. DNA Cell Biol. 2010, 29:349-356.
26. Grochola L.F., Muller T.H., Bond G.L., Taubert H., Udelnow A., Wurl P. MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation. Pancreas 2010, 39:76-80.
27. Hamid S., Yang Y.H., Peng K.N., Ismail S.M., Zain R.B., Lim K.P., Wan Mustafa W.M., Abraham M.T., Teo S.H., Cheong S.C. MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset. Oral Oncol. 2009, 45:496-500.
28. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
29. Hirata H., Hinoda Y., Kikuno N., Kawamoto K., Suehiro Y., Tanaka Y., Dahiya R. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin. Cancer Res. 2007, 13:4123-4129.
30. Hirata H., Hinoda Y., Kikuno N., Suehiro Y., Shahryari V., Ahmad A.E., Tabatabai Z.L., Igawa M., Dahiya R. Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J. Urol. 2009, 181:1907-1912.
31. Hirschhorn J.N., Lohmueller K., Byrne E., Hirschhorn K. A comprehensive review of genetic association studies. Genet. Med. 2002, 4:45-61.
32. Hong Y., Miao X., Zhang X., Ding F., Luo A., Guo Y., Tan W., Liu Z., Lin D. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res. 2005, 65:9582-9587.
33. Horikawa Y., Nadaoka J., Saito M., Kumazawa T., Inoue T., Yuasa T., Tsuchiya N., Nishiyama H., Ogawa O., Habuchi T. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol. Rep. 2008, 20:49-55.
34. Hu Z., Jin G., Wang L., Chen F., Wang X., Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol. Biomarkers Prev. 2007, 16:2717-2723.
35. Hu Z., Ma H., Lu D., Qian J., Zhou J., Chen Y., Xu L., Wang X., Wei Q., Shen H. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int. J. Cancer 2006, 118:1275-1278.
36. Jun H.J., Park S.H., Lee W.K., Choi J.E., Jang J.S., Kim E.J., Cha S.I., Kim D.S., Kam S., Kim C.H., Kang Y.M., Jung T.H., Park J.Y. Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer. Mol. Carcinog 2007, 46:100-105.
37. Kang S., Wang D.J., Li W.S., Wang N., Zhou R.M., Sun D.L., Duan Y.N., Li S.Z., Li X.F., Li Y. Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women. Int. J. Gynecol. Cancer 2009, 19:572-577.
38. Khatri R.G., Navaratne K., Weil R.J. The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme. J. Neurosurg. 2008, 109:842-848.
39. Kibel A.S., Jin C.H., Klim A., Luly J., Roehl K.A., Wu W.S., Suarez B.K. Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. Prostate 2008, 68:1179-1186.
40. Kinyamu H.K., Archer T.K. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol. Cell. Biol. 2003, 23:5867-5881.
41. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature 1997, 387:299-303.
42. Lang A., Palmeback Wegman P., Wingren S. The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer. Oncol. Rep 2009, 22:575-579.
43. Leu J.D., Lin I.F., Sun Y.F., Chen S.M., Liu C.C., Lee Y.J. Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J. Gastroenterol. 2009, 15:5592-5597.
44. Li G., Zhai X., Zhang Z., Chamberlain R.M., Spitz M.R., Wei Q. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 2006, 27:2028-2033.
45. Lind H., Zienolddiny S., Ekstrom P.O., Skaug V., Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int. J. Cancer 2006, 119:718-721.
46. Liu G., Wheatley-Price P., Zhou W., Park S., Heist R.S., Asomaning K., Wain J.C., Lynch T.J., Su L., Christiani D.C. Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk. Int. J. Cancer 2008, 122:915-918.
47. Liu J.N., Zhang X.M., Guo Y.L., Sun T., Lin D.X., Wen T. Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population. Chin. J. Oncol. 2008, 30:335-338. (in Chinese with an English abstract).
48. Ma H., Hu Z., Zhai X., Wang S., Wang X., Qin J., Jin G., Liu J., Wei Q., Shen H. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett. 2006, 240:261-267.
49. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22:719-748.
50. Marcel V., Palmero E.I., Falagan-Lotsch P., Martel-Planche G., Ashton-Prolla P., Olivier M., Brentani R.R., Hainaut P., Achatz M.I. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. J. Med. Genet. 2009, 46:766-772.
51. Meissner Rde V., Barbosa R.N., Fernandes J.V., Galvao T.M., Galvao A.F., Oliveira G.H. No association between SNP309 promoter polymorphism in the MDM2 and cervical cancer in a study from northeastern Brazil. Cancer Detect. Prev. 2007, 31:371-374.
52. Michael D., Oren M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 2003, 13:49-58.
53. Millikan R.C., Heard K., Winkel S., Hill E.J., Massa B., Mayes L., Williams P., Holston R., Conway K., Edmiston S., de Cotret A.R. No association between the MDM2 -309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol. Biomarkers Prev. 2006, 15:175-177.
54. Misra C., Majumder M., Bajaj S., Ghosh S., Roy B., Roychoudhury S. Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. Mol. Carcinog. 2009, 48:790-800.
55. Mittelstrass K., Sauter W., Rosenberger A., Illig T., Timofeeva M., Klopp N., Dienemann H., Meese E., Sybrecht G., Woelke G., Cebulla M., Degen M., Morr H., Drings P., Groeschel A., Kreymborg K.G., Haeussinger K., Hoeffken G., Schmidt C., Jilge B., Schmidt W., Ko Y.D., Taeuscher D., Chang-Claude J., Wichmann H.E., Bickeboeller H., Risch A. Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene. BMC Cancer 2008, 8:113.
56. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
57. Nakashima M., Kondo S., Shimizu Y., Wakisaka N., Murono S., Furukawa M., Yoshizaki T. Impact of MDM2 single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma. Acta Otolaryngol. 2008, 128:808-813.
58. Nan H., Qureshi A.A., Hunter D.J., Han J. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. Cancer Causes Control 2009, 20:171-179.
59. Nunobiki O., Ueda M., Yamamoto M., Toji E., Sato N., Izuma S., Okamoto Y., Torii K., Noda S. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum. Cell 2009, 22:101-106.
60. Ohmiya N., Taguchi A., Mabuchi N., Itoh A., Hirooka Y., Niwa Y., Goto H. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J. Clin. Oncol. 2006, 24:4434-4440.
61. Onat O.E., Tez M., Ozcelik T., Toruner G.A. MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res. 2006, 26:3473-3475.
62. Park S.H., Choi J.E., Kim E.J., Jang J.S., Han H.S., Lee W.K., Kang Y.M., Park J.Y. MDM2 309T>G polymorphism and risk of lung cancer in a Korean population. Lung Cancer 2006, 54:19-24.
63. Paulin F.E., O'Neill M., McGregor G., Cassidy A., Ashfield A., Ali C.W., Munro A.J., Baker L., Purdie C.A., Lane D.P., Thompson A.M. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer 2008, 8:281.
64. Perfumo C., Parodi S., Mazzocco K., Defferrari R., Inga A., Scarra G.B., Ghiorzo P., Haupt R., Tonini G.P., Fronza G. MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma. Pediatr. Blood Cancer 2009, 53:576-583.
65. Petenkaya A., Bozkurt B., Akilli-Ozturk O., Kaya H.S., Gur-Dedeoglu B., Yulug I.G. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res. 2006, 26:4975-4977.
66. Phillips C.L., Gerbing R., Alonzo T., Perentesis J.P., Harley I.T., Meshinchi S., Bhatla D., Radloff G., Davies S.M. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr. Blood Cancer 2010, 55:248-253.
67. Pine S.R., Mechanic L.E., Bowman E.D., Welsh J.A., Chanock S.C., Shields P.G., Harris C.C. MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 2006, 15:1559-1561.
68. Schmidt M.K., Reincke S., Broeks A., Braaf L.M., Hogervorst F.B., Tollenaar R.A., Johnson N., Fletcher O., Peto J., Tommiska J., Blomqvist C., Nevanlinna H.A., Healey C.S., Dunning A.M., Pharoah P.D., Easton D.F., Dork T., Van't Veer L.J. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res. 2007, 67:9584-9590.
69. Singh V., Rastogi N., Mathur N., Singh K., Singh M.P. Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann. Epidemiol. 2008, 18:48-57.
70. Sotamaa K., Liyanarachchi S., Mecklin J.P., Jarvinen H., Aaltonen L.A., Peltomaki P., de la Chapelle A. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin. Cancer Res. 2005, 11:6840-6844.
71. Stoehr R., Hitzenbichler F., Kneitz B., Hammerschmied C.G., Burger M., Tannapfel A., Hartmann A. Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics. Br. J. Cancer 2008, 99:78-82.
72. Sun Y.F., Leu J.D., Chen S.M., Lin I.F., Lee Y.J. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer. BMC Cancer 2009, 9:13.
73. Terry K., McGrath M., Lee I.M., Buring J., De Vivo I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol. Biomarkers Prev. 2008, 17:983-986.
74. Toffoli G., Biason P., Russo A., De Mattia E., Cecchin E., Hattinger C.M., Pasello M., Alberghini M., Ferrari C., Scotlandi K., Picci P., Serra M. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin. Cancer Res. 2009, 15:3550-3556.
75. Tu H.F., Chen H.W., Kao S.Y., Lin S.C., Liu C.J., Chang K.W. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother. Oncol. 2008, 87:243-252.
76. Ueda M., Yamamoto M., Nunobiki O., Toji E., Sato N., Izuma S., Okamoto Y., Torii K., Noda S. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum. Cell 2009, 22:49-54.
77. Walsh C.S., Miller C.W., Karlan B.Y., Koeffler H.P. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol. Oncol. 2007, 104:660-664.
78. Wang X., Yang J., Ho B., Yang Y., Huang Z., Zhang Z., Zhang G. Interaction of Helicobacter pylori with genetic variants in the MDM2 promoter, is associated with gastric cancer susceptibility in Chinese patients. Helicobacter 2009, 14:114-119.
79. Wasielewski M., Nagel J.H., Brekelmans C., Klijn J.G., van den Ouweland A., Meijers-Heijboer H., Schutte M. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res. Treat. 2007, 104:153-157.
80. Wilkening S., Bermejo J.L., Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 2007, 28:2262-2267.
81. Wilkening S., Hemminki K., Rudnai P., Gurzau E., Koppova K., Forsti A., Kumar R. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin. Br. J. Dermatol. 2007, 157:375-377.
82. Wilkening S., Bermejo J.L., Burwinkel B., Klaes R., Bartram C.R., Meindl A., Bugert P., Schmutzler R.K., Wappenschmidt B., Untch M., Hemminki K., Forsti A. The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer. Cancer Res. 2006, 66:646-648.
83. Wu Y.W., Prakash K.M., Rong T.Y., Li H.H., Xiao Q., Tan L.C., Au W.L., Ding J.Q., Chen S.D., Tan E.K. Lingo2 variants associated with essential tremor and Parkinson's disease. Hum. Genet. 2011, 6:611-615.
84. Xiao M., Zhang L., Zhu X., Huang J., Jiang H., Hu S., Liu Y. Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. BMC Cancer 2010, 10:147.
85. Xiong X., Wang M., Wang L., Liu J., Zhao X., Tian Z., Wang J. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk. Res. 2009, 33:1454-1458.
86. Yang M., Guo Y., Zhang X., Miao X., Tan W., Sun T., Zhao D., Yu D., Liu J., Lin D. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 2007, 28:1996-2001.
87. Yarden R.I., Friedman E., Metsuyanim S., Olender T., Ben-Asher E., Papa M.Z. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res. Treat. 2008, 111:497-504.
88. Zauberman A., Flusberg D., Haupt Y., Barak Y., Oren M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res. 1995, 23:2584-2592.
89. Zhang X., Miao X., Guo Y., Tan W., Zhou Y., Sun T., Wang Y., Lin D. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum. Mutat. 2006, 27:110-117.
90. Zhang Z., Zhang R. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr. Cancer Drug Targets 2005, 5:9-20.
91. Zhou G., Zhai Y., Cui Y., Zhang X., Dong X., Yang H., He Y., Yao K., Zhang H., Zhi L., Yuan X., Qiu W., Shen Y., Qiang B., He F. MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin. Cancer Res. 2007, 13:2627-2633.